Logo image
Back
Ceftaroline for Suspected or Confirmed Invasive Methicillin-Resistant Staphylococcus aureus: A Pharmacokinetic Case Series
Journal article   Peer reviewed

Ceftaroline for Suspected or Confirmed Invasive Methicillin-Resistant Staphylococcus aureus: A Pharmacokinetic Case Series

Jeffrey J Cies, Wayne S Moore, 2nd, Adela Enache and Arun Chopra
Pediatric critical care medicine, v 19(6), pp e292-e299
Jun 2018
DOI: https://doi.org/10.1097/PCC.0000000000001497
PMID: 29419605
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

Adolescent Anti-Bacterial Agents - pharmacokinetics Anti-Bacterial Agents - therapeutic use Cephalosporins - pharmacokinetics Cephalosporins - therapeutic use Child Child, Preschool Critical Illness - therapy Female Humans Infant Intensive Care Units, Pediatric Male Methicillin-Resistant Staphylococcus aureus - drug effects Prospective Studies Retrospective Studies Staphylococcal Infections - drug therapy Treatment Outcome
To describe the ceftaroline pharmacokinetics in critically ill children treated for suspected or confirmed methicillin-resistant Staphylococcus aureus infections, including blood stream infection and describe the microbiological and clinical outcomes. Retrospective electronic medical record review. Free-standing tertiary/quaternary pediatric children's hospital. Critically ill children receiving ceftaroline monotherapy or combination therapy for suspected or confirmed methicillin-resistant S. aureus infections in the PICU. None. Seven patients, three females (43%), and four males (57%), accounted for 33 ceftaroline samples for therapeutic drug management. A median of four samples for therapeutic drug management was collected per patient (range, 2-9 samples). The median age was 7 years (range, 1-13 yr) with a median weight of 25.5 kg (range, 12.6-40.1 kg). Six of seven patients (86%) demonstrated an increase in volume of distribution, five of seven patients (71%) demonstrated an increase in clearance, and 100% of patients demonstrated a shorter half-life estimate as compared with the package insert estimate. Six of seven patients (85.7%) had documented methicillin-resistant S. aureus growth from a normally sterile site with five of six (83.3%) having documented BSI, allowing six total patients to be evaluated for the secondary objective of microbiological and clinical response. All six patients achieved a positive microbiological and clinical response for a response rate of 100%. These data suggest the pharmacokinetics of ceftaroline in PICU patients is different than healthy pediatric and adult patients, most notably a faster clearance and larger volume of distribution. A higher mg/kg dose and a more frequent dosing interval for ceftaroline may be needed in PICU patients to provide appropriate pharmacodynamic exposures. Larger pharmacokinetic, pharmacodynamic, and interventional treatment trials in the PICU population are warranted.

Metrics

7 Record Views
23 citations in Web of Science
24 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Critical Care Medicine
Pediatrics
Logo image